Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by CX Institutional

CX Institutional lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 68,647 shares of the biopharmaceutical company's stock after buying an additional 4,360 shares during the quarter. CX Institutional's holdings in Gilead Sciences were worth $7,692,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of GILD. Bridgewater Associates LP increased its holdings in Gilead Sciences by 122.7% during the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock worth $42,577,000 after purchasing an additional 253,994 shares during the period. Nissay Asset Management Corp Japan ADV increased its stake in shares of Gilead Sciences by 5.2% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after buying an additional 14,009 shares during the period. Ontario Teachers Pension Plan Board increased its stake in shares of Gilead Sciences by 54.6% during the fourth quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock valued at $3,422,000 after buying an additional 13,086 shares during the period. Mufg Securities Americas Inc. bought a new stake in shares of Gilead Sciences in the fourth quarter valued at about $1,699,000. Finally, Convergence Investment Partners LLC lifted its stake in Gilead Sciences by 15.8% in the fourth quarter. Convergence Investment Partners LLC now owns 68,447 shares of the biopharmaceutical company's stock worth $6,322,000 after acquiring an additional 9,330 shares during the period. 83.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target for the company. Bank of America increased their target price on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Morgan Stanley boosted their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Piper Sandler raised their price objective on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Finally, The Goldman Sachs Group lifted their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Nine investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Stock Performance

NASDAQ GILD traded up $0.39 during trading hours on Thursday, reaching $109.69. The stock had a trading volume of 2,093,592 shares, compared to its average volume of 8,806,780. The stock has a fifty day moving average of $105.40 and a 200 day moving average of $101.91. The stock has a market cap of $136.45 billion, a P/E ratio of 296.46, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a 52-week low of $62.69 and a 52-week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the previous year, the firm posted ($1.32) earnings per share. The firm's quarterly revenue was down .3% on a year-over-year basis. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's payout ratio is presently 66.53%.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the transaction, the insider now owns 121,152 shares in the company, valued at $13,026,263.04. The trade was a 18.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total value of $249,550.00. Following the transaction, the chief financial officer now owns 165,674 shares in the company, valued at $16,537,578.68. This represents a 1.49% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 43,000 shares of company stock worth $4,630,310. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.